Hajjo Rima, Sabbah Dima A, Bardaweel Sanaa K, Tropsha Alexander
Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, P.O. Box 130, Amman 11733, Jordan.
Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, The University of North Carlina at Chapel Hill, Chapel Hill, NC 27599, USA.
Diagnostics (Basel). 2021 Apr 21;11(5):742. doi: 10.3390/diagnostics11050742.
The identification of reliable and non-invasive oncology biomarkers remains a main priority in healthcare. There are only a few biomarkers that have been approved as diagnostic for cancer. The most frequently used cancer biomarkers are derived from either biological materials or imaging data. Most cancer biomarkers suffer from a lack of high specificity. However, the latest advancements in machine learning (ML) and artificial intelligence (AI) have enabled the identification of highly predictive, disease-specific biomarkers. Such biomarkers can be used to diagnose cancer patients, to predict cancer prognosis, or even to predict treatment efficacy. Herein, we provide a summary of the current status of developing and applying Magnetic resonance imaging (MRI) biomarkers in cancer care. We focus on all aspects of MRI biomarkers, starting from MRI data collection, preprocessing and machine learning methods, and ending with summarizing the types of existing biomarkers and their clinical applications in different cancer types.
识别可靠且非侵入性的肿瘤生物标志物仍然是医疗保健领域的首要任务。目前仅有少数生物标志物被批准用于癌症诊断。最常用的癌症生物标志物来源于生物材料或成像数据。大多数癌症生物标志物缺乏高特异性。然而,机器学习(ML)和人工智能(AI)的最新进展使得能够识别具有高度预测性、疾病特异性的生物标志物。此类生物标志物可用于诊断癌症患者、预测癌症预后,甚至预测治疗效果。在此,我们总结了磁共振成像(MRI)生物标志物在癌症治疗中的开发和应用现状。我们关注MRI生物标志物的各个方面,从MRI数据收集、预处理和机器学习方法,到总结现有生物标志物的类型及其在不同癌症类型中的临床应用。